Colon to Rectum

Aliment Pharmacol Ther. 2024;59(1):89–99

Spartz EJ, DeDecker LC, Fansiwala KM, Noorian S, Roney AR, Hakimian S, Sauk JS, Chen PH, Limketkai BN

Recent trends and risk factors associated with Clostridioides difficile infections in hospitalized patients with inflammatory bowel disease


Background: Clostridioides difficile infections (CDIs) are common among patients with inflammatory bowel disease (IBD) and can mimic and exacerbate IBD flares, thus warranting appropriate testing during flares.
Aims: To examine recent trends in rates of CDI and associated risk factors in hospitalized IBD patients, which may better inform targeted interventions to mitigate the risk of infection.
Methods: This is a retrospective analysis using the Nationwide Readmissions Database from 2010 to 2020 of hospitalized individuals with Crohn’s disease (CD) or ulcerative colitis (UC). Longitudinal changes in rates of CDI were evaluated using International Classification of Diseases codes. Multivariable logistic regression evaluated the association between patient- and hospital-related factors and CDI.
Results: There were 2,521,935 individuals with IBD who were hospitalized at least once during the study period. Rates of CDI in IBD-related hospitalizations increased from 2010 to 2015 (CD: 1.64–3.32%, p < 0.001; UC: 4.15–5.81%, p < 0.001), followed by a steady decline from 2016 to 2020 (CD: 3.15–2.27%, p < 0.001; UC: 5.04–4.27%, p < 0.001). In multivariable models, CDI was associated with the Charlson-Deyo comorbidity index, public insurance, and hospital size. CDI was associated with increased mortality.

Conclusions: Rates of Clostridioides difficile infection (CDI) among hospitalized patients with inflammatory bowel disease (IBD) had initially increased, but have declined since 2015. Increased comorbidity, large hospital size, public insurance, and urban teaching hospitals were associated with higher rates of CDI. CDI was associated with increased mortality in hospitalized patients with IBD. Continued vigilance, infection control, and treatment of CDI can help continue the trend of declining infection rates.

E.J. Spartz, M.D., Center for Inflammatory Bowel Diseases, UCLA School of Medicine, Los Angeles, CA, USA, E-Mail: espartz@gmail.com

DOI: 10.1111/apt.17777

Back to overview

this could be of interest:

Treatment of non-constipated irritable bowel syndrome with the histamine 1 receptor antagonist ebastine: A randomized, double-blind, placebo-controlled trial

Gut. 2024;73(3):459–69

Dysbiosis and associated stool features improve prediction of response to biological therapy in inflammatory bowel disease

Gastroenterology. 2024;166(3):483–95

More articles on the topic